Safety and efficacy of primary thromboprophylaxis in cancer patients

• I. García Escobar ^[1] ; M. Antonio Rebollo ^[5] ; S. García Adrián ^[2] ; A. Rodríguez-Garzotto ^[3] ; A. Muñoz Martín ^[4] ; Spanish Society of Medical Oncology
  1. [1] Hospital San Pedro de Alcántara

     Hospital San Pedro de Alcántara

     Cáceres, España

     
  2. [2] Hospital de Móstoles

     Hospital de Móstoles

     Móstoles, España

     
  3. [3] Hospital Universitario Príncipe de Asturias

     Hospital Universitario Príncipe de Asturias

     Alcalá de Henares, España

     
  4. [4] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  5. [5] ICO-Hospital Duran i Reynalds, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 1 (January 2017), 2017, págs. 1-11
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cancer is often complicated by venous thromboembolism (VTE), a common and potentially fatal complication associated with poor prognosis in these patients. An increased incidence of VTE is being observed due to the advanced age of cancer patients, the thrombogenic effect of novel drugs and advances in the diagnosis of related complications. In this review, we look at five different risk groups of cancer patients with an increased probability of developing VTE, including hospitalized patients undergoing chemotherapy, patients undergoing a surgical procedure, ambulatory patients undergoing chemotherapy, patients with a central venous access and patients receiving antiangiogenic drugs or anticoagulant therapy due to previous chronic diseases. The aim of this review is to summarize the most important clinical evidence reported to date on the suitability of primary thromboprophylaxis to cancer patients. Recommendations have drawn up for each group based on current evidence and guidelines to facilitate decision-making in clinical practice.